行情

ERNA

ERNA

Eterna Therapeutics Inc
NASDAQ
3.210
-0.090
-2.73%
已收盘, 16:00 11/28 EST
开盘
3.120
昨收
3.300
最高
3.404
最低
3.120
成交量
7,450
成交额
1.98万
52周最高
127.60
52周最低
2.735
市值
944.42万
市盈率(TTM)
-0.3062
分时
5日
1月
3月
1年
5年
Eterna Therapeutics 收到纳斯达克的违规通知
Eterna Therapeutics 收到纳斯达克的违规通知
MT Newswires · 6天前
Eterna Therapeutics 可以选择从 Exacis 获得癌症治疗许可
Eterna Therapeutics 可以选择从 Exacis 获得癌症治疗许可
MT Newswires · 10/17 11:26
--Maxim 将布鲁克林免疫疗法从买入下调至持有
--Maxim 将布鲁克林免疫疗法从买入下调至持有
MT Newswires · 10/12 11:24
Brooklyn ImmunoTherapeutics 将于 10 月更名为 Eterna Therapeutics;股价上涨
Brooklyn ImmunoTherapeutics 将于 10 月更名为 Eterna Therapeutics;股价上涨
MT Newswires · 10/11 11:51
Brooklyn ImmunoTherapeutics 披露与 Factor Bioscience 的协议
Brooklyn ImmunoTherapeutics 披露与 Factor Bioscience 的协议
MT Newswires · 09/15 16:58
ERNA 简况
Eterna Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing advanced therapies using Messenger RNA (mRNA) cell engineering technology. The Company is engaged in developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its product pipeline is based on patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. It formulates mRNA using lipid nanoparticle (LNP) technology. The ToRNAdo delivery system surrounds and protects the mRNA cargo, enabling delivery into human cells. The Company has licensed a portfolio of over 100 patents covering key cell engineering technologies, including therapeutic gene editing in clinical development. It has multiple cell and gene-editing therapies in preclinical development for various indications.

微牛提供Eterna Therapeutics Inc(NASDAQ-ERNA)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ERNA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ERNA股票基本功能。